For investor audiences and financial/business media only
Continued strong commercial performance and 12 positive Phase III programme readouts in the year to date
In the first nine months we saw strong commercial momentum with total revenue up 7% and Core EPS up 14%, driven by our diverse therapy areas and global presence. We have had approvals for four new medicines and reported 12 positive Phase III programme readouts with a collective peak year revenue potential well in excess of ten billion dollars. Our rich series of upcoming readouts in 2027 has a potential of more than twenty billion dollars.
With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on track to deliver our 2030 ambition and to sustain growth through the next decade.”
Download the 9M and Q3 2026 results documents
Announcement
Presentation
Clinical trials appendix
Key performance elements for 9M 2026
(Growth numbers at constant exchange rates (CER1))
- Total Revenue up 7%, with double-digit growth in Oncology, R&I and Rare Disease offsetting headwinds from Farxiga and Brilinta loss of exclusivity and volume-based procurement in China
Core Operating profit and Core2 Earnings Per Share (EPS) increased 14%
47 approvals in major regions since Q4 2025 results, including first approvals for four new medicines (Etcamah, Baxfendy, Klygefa and Amlypave)
First Phase III data for three new molecular entities (NMEs) (tozorakimab, efzimfotase alfa and sonesitatug vedotin)
How did AstraZeneca perform financially?
| Revenue and EPS Summary | 9M 2026 | Q3 2026 | ||||
|---|---|---|---|---|---|---|
| $m | % Change Actual | % Change CER | $m | % Change Actual | % Change CER | |
| - Product Sales | 43,962 | 7 | 5 | 15,066 | 5 | 5 |
| - Alliance Revenue | 2,806 | 33 | 32 | 1,107 | 36 | 36 |
| Product Revenue | 46,768 | 8 | 6 | 16,173 | 7 | 7 |
| Collaboration Revenue | 113 | 22 | 23 | 36 | >3x | >3x |
| Total Revenue | 46,881 | 8 | 7 | 16,209 | 7 | 7 |
| Reported EPS ($) | 5.62 | 10 | 11 | 2.02 | 23 | 26 |
| Core EPS ($) | 8.00 | 14 | 14 | 2.79 | 17 | 19 |
GUIDANCE3
RECONFIRMED
Which Therapy Areas drove growth?
9M 2026 Total Revenue by Therapy Area. Growth at CER.
36% of revenue. Respiratory & Immunology grew +10%, CVRM (−14%), Infectious Disease (-12%)
| Therapy Area | $m | % Total Revenue | % Change CER |
|---|---|---|---|
| Oncology | 21,889 | 47 | 16 |
| - Cardiovascular, Renal & Metabolism | 8,728 | 19 | (14) |
| - Respiratory & Immunology | 7,268 | 16 | 10 |
| - Infectious Disease | 735 | 2 | (12) |
| BioPharmaceuticals | 16,731 | 36 | (5) |
| Rare Disease | 7,544 | 16 | 11 |
| Other Medicines | 717 | 2 | (8) |
What were the pipeline highlights?
projects in our pipeline NMEs or major life-cycle management in Phase II or Phase III NMEs delivered against target of 20 by 2030 NMEs in our late-stage pipeline
NMEs under review
180
116
14
20
2
Matthew Bowden
Company Secretary
AstraZeneca PLC
References
1. Constant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange movements between periods in 2026 vs. 2025. CER financial measures are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results.
2. Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. A full reconciliation between Reported EPS and Core EPS is provided in Tables 10 and 11 in the Financial Performance section of this document.
3. The Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the Cautionary statements section regarding forward-looking statements at the end of this announcement.